Clinical Trial Detail

NCT ID NCT02924766
Title A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

prostate cancer

Therapies

Apalutamide + Niraparib

Age Groups: adult senior

No variant requirements are available.